PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.\', \'Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, Los Angeles, CA, 90089, USA.\', \'Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, 90095, USA.\', \'Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA.\', \'Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, 90095, USA.\', \'Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA. liliyang@ucla.edu.\', \'Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, 90095, USA. liliyang@ucla.edu.\', \'Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA. liliyang@ucla.edu.\', \'Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, 90095, USA. liliyang@ucla.edu.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13287-022-02787-2
?:hasPublicationType
?:journal
  • Stem cell research & therapy
is ?:pmid of
?:pmid
?:pmid
  • 35313965
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all